



UNIVERSITI PUTRA MALAYSIA

**APPLICATION OF COMPARATIVE GENOMIC HYBRIDIZATION AND
FLUORESCENT IN SITU HYBRIDIZATION TECHNIQUES ON HUMAN
GLIOMA CELL LINES TREATED WITH BIS[S-METHYL-a-N-(2 -
FURYLMETHYLKETONE) DITHIOCARBAZATO] CADMIUM(II)**

SUHAILI ABU BAKAR

FPSK(M) 2004 5

**APPLICATION OF COMPARATIVE GENOMIC HYBRIDIZATION AND
FLUORESCENT *IN SITU* HYBRIDIZATION TECHNIQUES ON HUMAN
GLIOMA CELL LINES TREATED WITH BIS[S-METHYL- β -N-(2-
FURYL METHYLKETONE) DITHIOCARBAZATO] CADMIUM(II)**

By

SUHAILI ABU BAKAR

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in
Fulfilment of the Requirements for the Master of Science**

September 2004



DEDICATION

This thesis is dedicated to my beloved husband, Mohd Taufik Mahpop, my son, Muhammad Haiman Fakhruddin and my parents, Siti Besah and Abu Bakar, without whom none of this would have been even possible.



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

APPLICATION OF COMPARATIVE GENOMIC HYBRIDIZATION AND FLUORESCENT *IN SITU* HYBRIDIZATION TECHNIQUES ON HUMAN GLIOMA CELL LINES TREATED WITH BIS[S-METHYL- β -N-(2-FURYL METHYLKETONE) DITHIOCARBAZATO] CADMIUM(II)

By

SUHAILI ABU BAKAR

September 2004

Chairman: Associate Professor Rozita Rosli, Ph D.

Faculty : Medicine and Health Sciences

Comparative genomic hybridization (CGH) and fluorescent *in situ* hybridization (FISH) have become invaluable tools for the diagnosis and identification of numerous chromosomal aberrations either in haematological malignancies or solid tumors. CGH is a modified *in situ* hybridization technique that allows detection and mapping of DNA sequence copy differences between two genomes in a single experiment whereas FISH is a quantitative analysis of specific chromosomes and genes. In this study, both techniques were used in three gliomas cell lines; A172 (glioblastoma), U87 MG (astrocytoma grade III) and T98G (glioblastoma multiforme) to investigate the genomic imbalance and to detect cancer-related genes before and after treatment with a new synthetic cadmium compound. Bis[S-methyl- β -N-(2-furylmethylketone) dithiocarbazato] cadmium(II) (SMDB-Cd) was synthesized at the Chemistry Department, Faculty of Science, Universiti Putra Malaysia and has shown to have potential as an anticancer agent. The EC₅₀ values for SMDB-Cd on A172, U87MG, T98G and HCN-2 were at 0.7, 0.3, 0.4 and 1.5 μ g/ml respectively, while tamoxifen



which is commonly used to treat brain cancer were at 7.0, 5.0, 4.0 and 6.0 $\mu\text{g/ml}$. CGH data indicated that these three cell lines have various DNA copy number changes; the most frequent DNA gains found were at 7p and 13q, and losses of chromosome 9p, 17p and 19q indicate that these regions contain candidate tumor suppressor genes involved in gliomas. Upon treatment with SMDB-Cd at those EC_{50} concentrations, U87 MG was shown to be more sensitive to SMDB-Cd compared to A172 and T98G. Chromosome 7p did not show any changes in DNA amplification or deletion. Involvement of one of the important tumor suppressor genes in many human cancers, p53, which is mapped to the short arm of chromosome 17, was then examined. The amplification status of this region was evaluated by using FISH through the locus specific p53 (17p13.1) probe. About 60% of cells were detected to have deletion on one or both copies of the p53 gene in A172 and U87MG. However, two copies of the p53 gene were detected in T98G, which means there is no deletion of p53. These results agree with the previous study on the association of p53 mutation with different subtypes of gliomas. After treatment with SMDB-Cd, p53 level was observed to be amplified in T98G. Increasing of p53 level may have been induced by the action of SMDB-Cd on the cells that inhibit cell growth and lead to cell damage. Thus, the combined use of CGH and FISH provided an efficient method for resolving the origin of aberrant chromosomal material unidentified by conventional cytogenetic analysis. CGH was observed to be a powerful tool in assisting the screening of amplification and deletion regions in glioma cell lines upon treatment with SMDB-Cd. Use of FISH to confirm the involvement of the p53 gene further enhances the validity of the technique.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

**PENGUNAAN TEKNIK PERBANDINGAN PENGHIBRIDAN GENOM DAN
PENGHIBRIDAN *IN SITU* FLUORESEN KE ATAS SEL - SEL GLIOMA
MANUSIA SELEPAS DIRAWAT DENGAN BIS[S-METHYL- β -N-(2-
FURYL METHYLKETONE) DITHIOCARBAZATO] CADMIUM(II)**

Oleh

SUHAILI ABU BAKAR

September 2004

Pengerusi : Profesor Madya Rozita Rosli, Ph D.

Fakulti : Perubatan dan Sains Kesihatan

Perbandingan penghibridan genom (CGH) dan penghibridan *in situ* fluoresen (FISH) telah menjadi teknik yang sangat bernilai dalam diagnosis dan pengenalpastian pelbagai kesilapan kromosom sama ada di dalam pertumbuhan kanser darah atau kanser solid. CGH adalah teknik penghibridan *in situ* yang telah diubah suai untuk mengesan dan merajahkan perbezaan rangkaian DNA di antara dua gen dalam satu kajian manakala FISH adalah teknik yang berasaskan analisa kuantitatif terhadap kromosom dan gen yang khusus. Di dalam kajian ini, kedua-dua teknik di gunakan keatas tiga jenis sel glioma; A172 (glioblastoma), U87MG (astrocytoma gred III) dan T98G (glioblastoma multiforme) untuk menyelidik ketidakseimbangan genom dan mengesan gen-gen yang berkait rapat dengan pembentukan kanser glioma sebelum dan selepas dirawat dengan sintetik kompon kadmiun. Bis[S-methyl- β -N-(2-furylmethylketone) dithiocarbazato] cadmium(II) (SMDB-Cd) yang disintesis di jabatan kimia, fakulti sains dan alam sekitar, Universiti Putra Malaysia telah menunjukkan potensi sebagai anti kanser. Nilai EC₅₀ untuk SMDB-Cd pada A172, U87MG, T98G dan HCN-2 adalah 0.7, 0.3, 0.4 dan



1.5 $\mu\text{g/ml}$ dibandingkan dengan tamoxifen yang selalu digunakan dalam merawat kanser otak iaitu 7.0, 5.0, 4.0 dan 6.0 $\mu\text{g/ml}$. CGH telah mengenal pasti pelbagai perubahan salinan DNA didalam ketiga – tiga sel tersebut; yang paling kerap dilihat adalah pertambahan DNA pada 7p dan 13q manakala kehilangan DNA adalah pada kromosom 9p, 17p dan 19q di mana bahagian – bahagian tersebut mengandungi gen supresor tumor yang terlibat dalam gliomas. Selepas dirawat dengan SMDB-Cd pada kepekatan EC_{50} , U87MG telah menunjukkan tindak balas yang lebih sensitive terhadap kompon tersebut berbanding dengan A172 dan T98G. Kromosom 7p tidak menunjukkan sebarang penambahan atau kehilangan DNA. Penglibatan satu gen supresor kanser, p53 yang terletak pada bahagian pendek kromosom 17 telah diuji. Status peningkatan bahagian ini telah dinilai dengan menggunakan FISH melalui probe khusus untuk loci p53 (17p13.1). Hampir 60% dari sel – sel A172 dan U87MG menunjukkan tiada salinan atau satu salinan gen p53 sahaja yang dilihat. Walau bagaimanapun, terdapat dua salinan gen p53 yang dikenal pasti didalam T98G bermakna tidak ada kehilangan gen p53. Keputusan ini bersetuju dengan kajian terdahulu mengenai hubungan gen p53 dengan jenis – jenis gliomas. Selepas diberi SMDB-Cd, terdapat peningkatan paras p53 di dalam T98G. Peningkatan paras p53 ini di dalam sel – sel yang dirawat mencadangkan kemungkinan tindakan kompon sintetik tersebut keatas sel yang menghalang pertumbuhan sel dan menyebabkan kemusnahan sel. Maka, kombinasi CGH dan FISH memberikan kaedah yang berkesan dalam menyelesaikan permulaan kepelbagaian kromosom yang tidak dapat dikenal pasti melalui analisis sitogenetik konvensional. Keputusan ini menunjukkan CGH adalah satu teknik yang boleh digunakan dalam penyaringan peningkatan dan kehilangan bahagian-

bahagian yang terlibat dalam sel-sel glioma sama ada sebelum atau selepas dirawat dengan SMDB-Cd. FISH sebagai pengesahan teknik kepada gen p53 tersebut yang meningkatkan lagi kesahihan kaedah tersebut.

ACKNOWLEDGEMENTS

I am giving all of my thanks to Allah S. W. T whose blessings have accompanied me with the energy, ideas and time in every step of the way in finishing this thesis work and made it a possible task.

My appreciation goes to Associate Professor Dr. Rozita Rosli, Associate Professor Dr. Sabariah Abdul Rahman and Dr. Chong Pei Pei for their effort in helping to make this thesis a success.

Sincere thanks are due to Shaban and Nazefah for helping and teaching me in doing cell culture work, Nasir and Kak Nurmawati for the additional important knowledge in the theory of cell culture technique.

Loving thanks to all my friends Sharizah Alimat, Thilakavathy, Zetty and Shikin, who played such important roles along the journey, as we mutually engaged in making sense of the various challenges we faced and in providing encouragement to each other at those time when it seemed impossible to carry on.

Last but not least, I would like to express my heartfelt thanks to my beloved husband Mohd Taufik, mother Siti Besah and father Abu Bakar for their endless encouragement, patient, care, financial and sacrifices that had helped me in my undertakings and to complete this research study successfully. To my son, Haiman Fakhrudin, thank you for allowing me to take part of your growing time.



TABLE OF CONTENTS

	Page
DEDICATION	2
ABSTRACT	3
ABSTRAK	5
ACKNOWLEDGEMENTS	8
APPROVAL	9
DECLARATION	11
LIST OF TABLES	14
LIST OF FIGURES	15
LIST OF ABBREVIATIONS	18
 CHAPTER	
I INTRODUCTION	20
Background of the Study	20
Objectives of the Study	27
II LITERATURE REVIEW	28
Molecular Cytogenetic Techniques	28
Fluorescence <i>in situ</i> hybridization (FISH)	28
Historical Perspectives	28
Principles of FISH	29
Technical Elements of FISH	31
Comparative Genomic Hybridization (CGH)	38
Principles of CGH	38
The CGH Technique	39
Application of FISH and CGH in medicine and biology	41
CGH and FISH in Solid Tumors, Hemopathies and other Disease	42
CGH and FISH in Brain Tumors	47
CGH and FISH in Gliomas; Astrocytomas	47
Human Cancer	50
Oncogenes	51
Tumor Suppressor Genes	54
p53	55
Brain Tumors	56
Background	56
Types of Brain Tumors	57
Gliomas	64
Astrocytomas	65
Human Cell Lines	67
A172	67
U87MG	67



	T98G	68
	Chemotherapy drugs	68
III	MATERIALS AND METHODS	72
	Cell lines and Cell Culture	72
	Cytotoxicity Assay	74
	MTT Assay	74
	Treatment of Cells with SMDB-Cd	75
	Extraction of Total Genomic DNA	76
	DNA Extraction from Cells	77
	DNA extraction from Normal Male Blood	78
	DNA Quantification	80
	Quantification of nucleic acids by Spectrophotometer	80
	Electrophoresis of DNA	81
	Probe preparation for CGH and FISH	81
	Nick Translation (Probe Labeling)	82
	Determination of Probe Size	83
	Probe for Fluorescence <i>in situ</i> Hybridization (FISH)	83
	Probe Mixture	84
	Preparing of Probe Mixture for CGH	84
	Preparing of Probe Mixture for FISH	85
	Slide Preparation	85
	Hybridization for CGH or FISH	86
	Slide Washing	87
	Computer-Assisted Image Analysis	88
IV	RESULTS	90
	MTT Assay (EC_{50})	90
	Morphological of gliomas cell lines	93
	DNA Laddering	96
	DNA Labeling	97
	Comparative Genomic Hybridization (CGH)	98
	Fluorescence <i>in situ</i> Hybridization (FISH)	110
V	DISCUSSION	114
VI	CONCLUSION	129
	REFERENCES	133
	APPENDICES	140
	BIODATA OF THE AUTHOR	141



LIST OF TABLES

Table	Page
1 Milestones in karyotyping and molecular cytogenetics (adapted from Rautenstrauß and Liehr, 2002).	21
2 Types of probes and FISH techniques used in routine molecular cytogenetic analyses (adapted from Rautenstrauß and Liehr, 2002).	33
3 Labeling strategies of probes (adapted from Rautenstrauß and Liehr, 2002).	35
4 Examples of oncogenes in human tumors (adapted from Macdonald and Ford, 1997).	53
5 Tumor Suppressor genes (adapted from King, 2000).	54
6 Tumors with deletions of 17p (adapted from Macdonald and Ford, 1997).	55
7 List of tumor classification by location, characteristic and cell origin (adapted from Otto, 2001).	59
8 TNM Classification of Brain Tumors (adapted from Otto, 2001).	62
9 Comparison of Kernohan and WHO Classification (adapted from Otto, 2001).	63
10 EC ₅₀ of the synthetic compounds, SMDB-Cd compared to tamoxifen on HCN-2, A172, U87MG and T98G cell lines. Values represent means of 3 observations.	91
11 Summarization of CGH profile of each cell line upon treatment with SMDB-Cd.	99

LIST OF FIGURES

Figure	Page
1 Principles of Fluorescence <i>in situ</i> hybridization (from University of Wisconsin - Madison Waisman Center Cytogenetics Lab, http://www.slh.wisc.edu/cytogenetics/procedures/FISH/FISH.html) Accessed on 14 th September 2000.	30
2 Principles of Fluorescence <i>in situ</i> hybridization (from University of Wisconsin - Madison Waisman Center Cytogenetics Lab, http://www.slh.wisc.edu/cytogenetics/procedures/FISH/FISH.html) Accessed on 14 th September 2000.	30
3 A schematic representation of comparative genomic hybridization analysis (adapted from Macdonald and Ford, 1997).	40
4 Synopsis of genetic alterations associated with the evolution and progression of human gliomas (adapted from Ohgaki <i>et al.</i> , 1993).	66
5 Cytotoxicity effect of tamoxifen on glioma cell lines A172, T98G and U87MG. Glioma cell lines were grown in 96-well microtiter plates and exposed to various concentrations for 72 hours and cytotoxicity was estimated by MTT assay.	92
6 Cytotoxicity effects of SMDB-Cd on glioma cell lines. Glioma cell lines T98G, A172 and U87MG were exposed to various concentrations for 72 hours and cytotoxicity was estimated by MTT assay.	92
7 Morphology of each cell line before treatment with SMDB-Cd. Panel A shows the morphology of A172 cells that appear elongated with astrocytic processes, panel B shows the morphology of U87MG cell that are more hexagonal and also has astrocytic process and panel C shows the morphology of T98G that appear as undifferentiated multiple shapes (20X magnification).	93
8 Morphology of each cell line that was treated with tamoxifen. Panels A, B and C show the morphology of A172, U87MG and T98G cells respectively, that were affected by the compound. Appearance of round cells indicating cell death (red arrow) was observed (10X magnification).	94

- 9 Morphology of each cell line that was treated with SMDB-Cd. Panels A, B and C show the morphology of A172, U87MG and T98G cells respectively, that were affected by the compound is shown as round cells indicating cell death (10X magnification). 95
- 10 DNA fragmentation in three gliomas cell lines after treatment with SMDB-Cd. Extracted DNA was analyzed on a 2% agarose gel. Lanes 1, 2 and 5 contain A172, U87MG and T98G untreated while lanes 3 and 4 are A172, U87MG and T98G treated SMDB-Cd at the EC₅₀ value. Lanes 6 and 7 show 98G treated with two concentrations of SMDB-Cd. 96
- 11 DNA labeling on the normal (reference) and tumor (test) cells that was carried out by using nick translation. The labeled DNA was analyzed on a 1% agarose gel to check the size of probe. (1) Positive control labeled with TRITC-dUTP, (2) Negative control labeled with TRITC-dUTP, (3) Negative control labeled with FITC-dUTP, (4) untreated A172 labeled with FITC-dUTP, (5) treated A172 labeled with FITC-dUTP, (6) untreated U87MG labeled with FITC-dUTP, (7) treated U87MG labeled with FITC-dUTP, M is the size marker (1kb). 97
- 12 Chromosome images that were taken using a special software for each different filter. (A) Images in DAPI staining, (B) Images in FITC filter, (C) Image in TRITC filter, (D) Karyotyping of the chromosome in DAPI staining and (E) Image of green to red ratio. 101
- 13 CGH profile for the negative control of the normal male peripheral blood lymphocytes. No abnormalities are detected. 102
- 14 CGH profile for the positive control. Small deletion near 1pter; gain of 1q, loss 9p, distal deletion on 11q and loss of 16q. For comparison, chromosomes 2 and X are normal. 103
- 15 The average green to red fluorescence ratio profiles of A172 before treatment with the SMDB-Cd computed from the 10 ratio images. 104
- 16 The average green to red fluorescence ratio profiles of A172 after treatment with the SMDB-Cd computed from the 10 ratio images. 105
- 17 Summary of genetic imbalances detected by CGH in U87MG before treatment with SMDB-Cd. The red line on the left of each chromosome indicate losses, whereas the green line on the right represent gains. 106
- 18 Summary of genetic imbalances detected by CGH in U87MG after treatment with SMDB-Cd. 107

- 19 Overview of genetic imbalances of T98G before treatment with SMDB-Cd. 108
- 20 Overview of green to red fluorescence profiles of T98G after treatment with SMDB-Cd. 109
- 21 FISH using Vysis LSI p53 (17p13.1) probe (yellow) to normal peripheral blood lymphocytes cells (100X magnification). 110
- 22 Results of FISH experiments using LSI p53 (17p13.1) probe (yellow) performed on chromosome preparations of A172 cell line. A) Untreated A172 with one copy of the p53 gene. B) Treated A172 with one copy of p53 gene (100X magnification). 111
- 23 Results of FISH experiments using LSI p53 (17p13.1) probe (yellow) Performed on chromosome preparations of U87MG cell line. A) Untreated U87MG with no copy of the p53 gene. B) Treated U87MG with no copy of p53 gene (100X magnification). 112
- 24 Results of FISH experiments using LSI p53 (17p13.1) probe (yellow) performed on chromosome preparations of T98G cell line. A) Untreated T98G with two copies of p53 gene. B) Treated T98G with multiple copies of p53 gene (100X magnification). 113



LIST OF ABBREVIATIONS

ATCC	American Typed Culture Collection
BACs	Bacterial artificial chromosomes
CCD	Charged couple device
Cd	Cadmium
CDK	Cyclin-dependent kinase
CGH	Comparative genomic hybridization
CIN	Chromosomal instability
CNS	Central Nervous System
DAPI	(4',6 – diamidino – 2 - - phenylindole)-
dATP	Deoxyadenosine triphosphate
del	Deletion
der	Derivative chromosome
DMEM	Dulbecco's Modified Eagle's media
DMSO	Dimethylsulfoxide
DNA	Deoxyribonucleic acid
dNTP	Deoxyribonucleotide triphosphate
dTTP	Deoxythymidine triphosphate
dUTP	Deoxyuridine triphosphate
EC ₅₀	Fifty-percent effective concentration
EGFR	Epidermal Growth Factor receptor
EMEM	Eagle's Minimal Essential media
FBS	Fetal bovine serum
FISH	Fluorescence <i>in situ</i> hybridization
FITC	Fluorescein isothiocyanate
FR	Fluorescent ratio
G banding	Giemsa banding
GBM	Glioblastoma multiforme
ISCN	The International System for Human Cytogenetic Nomenclature
ISH	<i>in situ</i> hybridization
LOH	Loss of heterozygosity



LOH	Loss of heterozygosity
LSI	Locus specific interphase
MDM2	Mouse double minute 2
MIN	Microsatellite instability
MTT	3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide
PACs	P1 filamentous phage artificial chromosomes
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
PDGF	Platelet-derived growth factor
PTEN	Phosphatase and tensin homolog
RB1	Retinoblastoma 1
RNA	Ribonucleic acid
SKY	Spectral karyotyping
SMDB-Cd	Cd(II) complex, bis [<i>S</i> -methyl- β - <i>N</i> -(2-furylmethyl-ketone)dithiocarbazato]Cd(II)
SSC	Standard sodium citrate
t	Translocation
TRITC	Texas red isothiocyanate
VEGF	Vascular endothelial growth factor
UV	Ultra violet
WCP	Whole chromosome probe
WHO	World Health Organization
YACs	Yeast artificial chromosomes

CHAPTER 1

INTRODUCTION

Currently, molecular cytogenetic techniques that are based on fluorescence *in situ* hybridization (FISH), have become invaluable tools for the diagnosis and identification of the numerous chromosomal aberrations which are associated with neoplastic disease, including both haematological malignancies and solid tumors. This is because the etiologies of these genetic diseases involve a complex interplay of numerous acquired genetic abnormalities, including amplification of oncogenes, deletion of tumor suppressor genes, gene rearrangements and loss or gain of function mutations (McNeil *et al.*, 2000).

Molecular cytogenetic techniques focus on specific chromosomes, chromosome regions and unique DNA sequences or genes as compared to standard cytogenetic techniques. With these techniques, some chromosomal abnormalities in nondividing cells can be detected with interphase nuclei instead of using standard cytogenetics which require actively dividing cells with metaphase nuclei. In other words, the molecular cytogenetic techniques can be used as a complementary technique which will expand the capabilities for making more accurate and refined cytogenetic diagnosis either for constitutional abnormalities or acquired chromosomal changes in cancer cells (Table 1) (Rautenstrauss and Liehr, 2002).



Table 1: Milestones in karyotyping and molecular cytogenetics (adapted from Rautenstrauss and Liehr, 2002)

Early findings	<p>Several authors in the 19th century</p> <p>1882 Flemming 1883 Roux</p> <p>1944 Avery <i>et al.</i></p> <p>1952 Hsu</p> <p>1953 Watson</p>	<ul style="list-style-type: none"> - Cell theory - Mendel's law of inheritance - First identification of mitotic figures <p>Behavior of chromosomes in a dividing cell</p> <p>DNA – transforming factor</p> <p>Hypotonic treatment of cells</p> <p>DNA double helix and genetic implications</p>
Pre – banding era	<p>1956 Tjio & Levan</p> <p>1958 Ford, Jacobs & Lajtha</p> <p>1959 Lejeune <i>et al.</i></p> <p>1960 Ford <i>et al.</i></p> <p>1960 Edwards <i>et al.</i>; Patau <i>et al.</i></p> <p>1960 Nowell & Hungerford</p>	<p>46 chromosomes</p> <p>First chromosome analysis in leukemia</p> <p>First chromosomal diseases:</p> <ul style="list-style-type: none"> - (Down's syndrome) trisomy of one of the smallest chromosomes - Turner's syndrome (monosomy X) <p>Denver Conference 23 human chromosome pairs divided by morphology into 7 groups (A - G)</p> <ul style="list-style-type: none"> - Trisomy for a D – group chromosome - Trisomy for an E – group chromosome <p>First identification of chromosomal disorder related to leukaemia</p>
Banding era	<p>1968 Carpasson <i>et al.</i></p> <p>1970 Chaudhuri <i>et al.</i>, Caspersson <i>et al.</i></p> <p>1970 Smith & Wilcox Kelly & Smith</p> <p>1971</p>	<p>Quinacrine mustard banding</p> <p>G and Q banding refined 450 – 550 bands/metaphase</p> <p>Birth of molecular genetics specific restriction endonucleases</p> <p>Paris Conference – first cytogenetic nomenclature of all 23 chromosome pairs</p>

	1973 Cohen <i>et al.</i> 1976 Yunis 1981	First report on cloning DNA using plasmids as vectors High resolution chromosome banding (up to 2000 bands/prophase)
FISH era	1981 Harper & Saunders; Malcolm <i>et al.</i> ; Gerhard <i>et al.</i> 1981 Langer <i>et al.</i> 1985 1986 Saiki <i>et al.</i> 1986 Pinkel <i>et al.</i> 1986 Deaven <i>et al.</i> 1988 Pinkel <i>et al.</i> Cremer <i>et al.</i> 1988 Lichter <i>et al.</i> 1990 Nederlof <i>et al.</i> 1991 1992 Telenius <i>et al.</i> 1992 Kallioniemi <i>et al.</i> 1995 Mitelman 1996 Schrock <i>et al.</i> Speicher <i>et al.</i> 1998 Choudoba <i>et al.</i>	Localization of single copy genes by insitu hybridization Biotin – labeled nucleotides International System for Human Cytogenetic Nomenclature (ISCN 1985) PCR technology Fluorescence hybridization Chromosome specific DNA libraries Fluorescence in situ hybridization with human chromosome specific libraries CISS hybridization Multi – color FISH Supplement to ISCN now including cancer cytogenetics DOP – PCR CGH – analysis Supplement to ISCN now including FISH nomenclature 24 – color karyotyping spectral karyotyping multicolor karyotyping High resolution bar coding

Improvement of the cytogenetic techniques from a conventional method such as G-banding to modern cytogenetic techniques such as fluorescence *in situ* hybridization (FISH) has enabled the finding of abnormalities in chromosome number and structure more quickly. FISH probes have been designed to detect specific regions of DNA and thus to elucidate abnormalities even at the level of the gene which cannot be detected by conventional techniques. Some of the advantages of FISH include the confirmation of chromosome breakpoints, an assessment of specific nucleic acid sequences and the ability to detect such sequences in non-dividing cells (*i.e.* interphase nuclei). Although FISH is an extremely useful technique, until recently only a few target sequences could be visualized simultaneously (McNeil *et al.*, 2000).

By contrast, comparative genomic hybridization (CGH) is widely used as a powerful method for detection and identification of chromosomal imbalances in a wide range of tumor samples (Kallioniemi *et al.*, 1992). The technique gives an overview of gains and losses of whole chromosomes or regions as well as amplifications and deletions of smaller segments. Identification of the chromosomal gains and losses is carried out by using differentially labeled tumor DNA and normal DNA. On visualizing the two different fluorochromes, differences in the intensity of fluorescence along the chromosome correspond to the loss or gain of genetic material in the tumor sample (McNeil *et al.*, 2000). Currently, the amplification of single genes have been documented, while deletions are detectable only on a larger scale (band size) (Barch *et al.*, 1997). The technique of CGH, which has also been referred to as copy number of



karyotyping may target a locus for molecular analysis or indicate pathways leading to tumor progression, recurrence and metastasis (Barch *et al.*, 1997).

In solid tumors, classical cytogenetic preparation has been less successful because of the difficulty of obtaining high quality representative metaphase chromosome preparations and to analyze the chromosomes that may not be representative of the tumor. Sometimes, the preparation of chromosome may have contamination of the specimen with normal tissue. The potential for multiple abnormal clones which contain high level of chromosomal rearrangements makes karyotyping analysis complicated. The complex nature of those rearrangements makes them indecipherable by banding techniques (Barch *et al.*, 1997). Therefore, the advent of molecular cytogenetic techniques in the late 1960s, which is the visualization of loci using the dynamic biochemical technique of *in situ* hybridization, has helped to detect chromosomal aberrations. In the case of solid tumors and leukaemia, obtaining of the metaphase chromosome spreads in conventional technique is difficult therefore in molecular cytogenetic, preparation of metaphase chromosome spreads from the sample is unnecessary that will help to analyze the chromosome in those diseases.

Research in cancer biology unequivocally shows that cancer tumors have a wide variety of aberrations in the organization and content of their genomes as compared with the genomes of normal cells. This genomic instability which is defined as the dynamic process of genomic changes in a tumor cell over time is a general feature of cancer cells. It displays an elevation of mutation rates during tumor progression that results in

